Health Canada Medical Device Registration & Approval (CMDR)

Canada medical device registration: MDL and MDEL are different

Health Canada regulates devices under the Medical Devices Regulations. Class I products generally do not need a product-specific Medical Device Licence (MDL); Class II, III and IV products do. Establishment licensing depends on the activities performed by manufacturers, importers and distributors, with specific exemptions.

An MDEL is not approval of each product. An MDL does not automatically license every importer or distributor in the supply chain. Define the legal manufacturer, device class, import route and commercial roles before preparing applications.

Classification, licence and quality evidence

Apply the Canadian classification rules, including the separate IVD rules, rather than importing a US or EU class. Class II–IV manufacturers generally need an ISO 13485 certificate issued through the Medical Device Single Audit Program (MDSAP) for the licensed scope. Confirm manufacturer/site identity and device coverage before using a certificate in the application.

Submission planning: REP and CESG

Health Canada’s mandatory REP notice took effect April 1, 2026 for the covered medical-device regulatory transactions. REP captures enrolment and application information; the Common Electronic Submissions Gateway (CESG) transmits the transaction. Do not describe every Canadian medical-device process, including MDEL, as the same product-licence submission workflow.

Establish the required company/dossier identifiers and gateway access early. Reconcile device names, identifiers, intended use, class, manufacturer, quality certificate and application category. Prepare the applicable structure and attachments, submit, retain acknowledgments and map questions to controlled responses. A successful electronic transmission is not a licensing decision.

Canadian labeling and local responsibilities

Sections 21–23 govern labeling. The language rule distinguishes products sold to the general public, for which specified information must be in both English and French, from other devices where English or French may initially suffice subject to the applicable obligations. Assess provincial and commercial requirements separately. Do not claim one identical bilingual rule for every professional-use device.

Canada does not impose one universal EU-style local Authorized Representative on every foreign manufacturer. A foreign manufacturer can hold an MDL, while importers/distributors and their MDEL duties must be assessed. Contracts should define complaint escalation, mandatory reporting, distribution records, recall cooperation, record access and who communicates with Health Canada.

Renewal, fees and postmarket compliance

Active MDEL holders generally submit annual licence review before April 1 and pay under the invoice terms; the application deadline is not automatically the fee-payment deadline. Licensed Class II–IV manufacturers have an annual renewal notification before November 1, with applicable right-to-sell fees handled under the current process. Maintain current MDSAP evidence, licence amendments and supply-chain permissions.

Government application fees, annual fees, audit costs and consulting costs are separate. Review standards depend on application type and exclude some applicant work; they are not a guaranteed total launch time. Budget for enrolment, testing, MDSAP readiness, dossier preparation, review questions and labeling changes.

After licensing, assess design, intended-use, site and quality-certificate changes before implementation. Maintain incident reporting, recall and safety-information procedures. Use the MDL/MDEL guide for the activity matrix and our pricing information to define the service scope. Pure Global can support the pathway and application while the manufacturer and licensed establishments retain their responsibilities.